Journal
LIFE SCIENCES
Volume 306, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2022.120861
Keywords
Alzheimer's disease; Amyloid beta; Tau tangles; Clinical trials
Funding
- School of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences University
Ask authors/readers for more resources
This article reviews the history of clinical trials for Alzheimer's disease and analyzes the reasons for their failures.
Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the All plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available